UNCY

Unicycive Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website unicycive.com
Employees(FY) 12
ISIN US90466Y1038

Performance

-7.57%

+41.03%

+59.07%

+5.92%

-21.17%

YTD

+19.0%

Profile

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Advanced Technical Analysis

Technical Analysis of UNCY 2024-12-20

The stock indicators reflect a mixed sentiment, with the Moving Average Score at 56 indicating a neutral to slightly bullish outlook, while the Oscillators Score at 40 and the Technical Score at 48 suggest a more cautious stance. Overall, the combined scores imply a neutral market sentiment, signaling potential indecision among investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of UNCY

Stock Rank

Recent News & Updates

2024-12-16 18:00
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics(Yahoo Finance)
2024-11-20 18:00
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference(Globenewswire)
2024-11-12 18:15
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-11-10 18:00
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis(Globenewswire)
2024-10-27 19:03
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024(Globenewswire)
2024-10-16 04:35
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024(Globenewswire)
2024-10-15 23:43
Results of Phase I trial shed positive light on UNI-494 for acute kidney injury(Yahoo Finance)
2024-10-13 19:03
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024(Globenewswire)
2024-10-11 07:03
Octagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics Inc(Yahoo Finance)
2024-10-08 19:03
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers(Globenewswire)
2024-09-23 19:03
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024(Globenewswire)
2024-09-19 20:35
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing(Yahoo Finance)
2024-09-16 00:07
Life Sciences Virtual Investor Forum Agenda Announced for September 19th(Yahoo Finance)
2024-09-15 19:03
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024(Globenewswire)
2024-09-04 19:03
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-09-02 19:03
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis(Globenewswire)
2024-08-25 19:03
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024(Globenewswire)
2024-08-13 19:10
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-07-16 19:03
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)(Globenewswire)
2024-07-10 19:03
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference(Globenewswire)
2024-07-09 19:03
Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)(Globenewswire)
2024-06-30 19:03
Unicycive Therapeutics Joins Russell Microcap Index(Globenewswire)
2024-06-24 19:30
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial(Globenewswire)
2024-05-27 19:03
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress(Globenewswire)
2024-05-22 19:03
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference(Globenewswire)
2024-05-14 19:03
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting(Globenewswire)
2024-05-13 10:53
UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-13 04:16
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-04-30 19:00
3 Top Penny Stocks to Buy for Explosive Returns: April Edition(Yahoo Finance)
2024-04-29 01:37
These 2 Strong Buy Penny Stocks Could Rally to $9, Says Piper Sandler(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.